Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13
- Title
- Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13
- Author
- 유대현
- Keywords
- Ankylosing spondylitis (AS); biosimilarity; infliximab; safety
- Issue Date
- 2013-10
- Publisher
- Wiley-Blackwell
- Citation
- Arthritis and Rheumatism, 2013, 65(12), P.3326-3326
- Abstract
- CT-P13 is an infliximab (INX) biosimilar recently approved by the European Medicine Agency. PLANETAS was a 54-week (wk) randomized double-blind parallel group multicenter Phase I study demonstrating pharmacokinetic equivalence of CT-P13 (5 mg/kg infusion every 8 wks) with INX, in patients (pts) with ankylosing spondylitis (AS) (Park W, ARD 2013;72(S3):516). Here we report results from the extension phase of the Phase I equivalence study, investigating long-term efficacy and safety of extended CT-P13 therapy and switching from INX to CT-P13 in pts with AS.
- URI
- http://onlinelibrary.wiley.com/doi/10.1002/art.38257/fullhttp://hdl.handle.net/20.500.11754/53206
- ISSN
- 0004-3591
- DOI
- 10.1002/art.38257
- Appears in Collections:
- COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML